Csaba Poroszlai is confirmed CEO of the company by the Board of Directors of Egis. Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.

Since the very beginning of the war in Ukraine, Egis Pharmaceuticals PLC has been committed to helping and supporting those in need in all possible ways.

Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October.  In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products.  Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing.

We have commemorated World Cancer Day.

In parallel to our mission, we serve people with all our knowledge and skills, so that they can live a long and healthy life. As Diamond Sponsor of the comprehensive nationwide health tests program, Egis Pharmaceuticals is devotedly engaged in the improvement of the Hungarian healthcare. Furthermore, thanks to the company’s commitment, hundreds of residents as well as the employees of the municipality of the 10th district (or Kőbánya) are offered free health tests within the ‘Egis Health and Prevention Days’.

On the occasion of the national holiday, Dr. István Hodász, CEO of Egis was granted the award ‘For the Hungarian Economy’ by Deputy Prime Minister and Minister of Finance Mihály Varga. The award is the most prestigious recognition to be given by the Minister of Finance on ministerial level for outstanding excellence and contribution to the Hungarian economy.

Egis tied as the most popular employer for science students and young graduates and early-stage professionals, found a new study analysing the preferences of young employees and graduates in Hungary.

As research and development are fundamental pillars of our strategy Egis is deeply committed to raise students’ interest in science and help the promising young minds develop their talents. That is why we have been supporting the annual ’Scientific and Innovation Talent Recruitment Contest for Youth’ for decades. This year, Egis’ prize went to undergraduate student Hunor Sebők.

Our Polish branch, Egis Polska, has been present on the market for 25 years and has made a tangible change in the country’s medical reality. Egis Polska introduces innovative medicines, including biological therapies, acts as a respected partner for the medical community, and is recognized as a valued employer, regularly awarded for creating a quality work environment.

The quality of life of millions depends on the availability of our medicines. Egis is one of the leading generic pharmaceutical companies in Central Easter Europe. We produce approximately 170 million boxes of drugs, 700 tonnes of active pharmaceutical ingredients, 5 billion tablets, capsules annually. Our products are available in 65 countries, and annually more than 30 million patients’ recovery depends on Egis Group’s continuous operation.